Stock Markets April 28, 2026 12:05 PM

Brussels Index Slides as Healthcare, Tech and Telecom Stocks Weigh on Market

BEL 20 closes down 0.39% as sector losses and commodity moves mark the session

By Jordan Park ABI APAM UCB
Brussels Index Slides as Healthcare, Tech and Telecom Stocks Weigh on Market
ABI APAM UCB

Belgian equities ended lower Tuesday in Brussels, with the BEL 20 declining 0.39% after weakness in Healthcare, Technology and Telecoms. Notable individual movers included gains for Anheuser Busch Inbev, Aperam and Ackermans & Van Haaren, while UCB, Melexis and Argen-X registered the largest declines. Market breadth favored decliners, and commodity prices moved with gold falling and oil rising. Major currency pairs were largely unchanged and the U.S. Dollar Index futures ticked higher.

Key Points

  • BEL 20 closed down 0.39% in Brussels, with Healthcare, Technology and Telecoms among the sectors weighing on the market.
  • Top individual gainers were Anheuser Busch Inbev (ABI), Aperam (APAM) and Ackermans & Van Haaren (ACKB); largest decliners were UCB, Melexis and Argen-X.
  • Commodity markets diverged: gold futures fell sharply while crude oil and Brent rose; major FX pairs were largely unchanged and the US Dollar Index futures ticked up.

Belgian stocks closed lower on Tuesday, with the benchmark BEL 20 index finishing the session down 0.39% in Brussels. Sector pressure from Healthcare, Technology and Telecoms contributed to the overall weakness.

Session movers

The session's top performers included Anheuser Busch Inbev SA NV (EBR:ABI), which advanced 1.95% or 1.22 points to finish at 63.84. Aperam SA (AS:APAM) gained 1.17% or 0.48 points to close at 41.56, and Ackermans & Van Haaren NV (EBR:ACKB) rose 1.10% or 3.00 points to end the day at 276.20.

On the downside, UCB SA (EBR:UCB) recorded the largest fall among the listed names, dropping 4.29% or 10.20 points to 227.70 at the close. Melexis NV (EBR:MLXS) declined 1.76% or 1.25 points to finish at 69.85, and Argen-X (EBR:ARGX) slipped 1.71% or 11.60 points to 665.60.

Market breadth and internals

Declining issues outpaced advancing ones on the Brussels Stock Exchange, with 50 stocks down versus 42 up, while 19 issues ended unchanged. That imbalance corresponded with the modest index decline.

Commodities and currencies

Precious and energy markets registered notable moves. Gold futures for June delivery fell 2.06% or 96.50 to $4,597.20 a troy ounce. In energy trading, crude oil for June delivery climbed 3.63% or 3.50 to reach $99.87 a barrel, and the July Brent contract rose 2.53% or 2.57 to trade at $104.26 a barrel.

Foreign exchange rates showed little change on the day. EUR/USD was essentially unchanged, moving 0.08% to 1.17, and EUR/GBP was flat, changing 0.13% to 0.87. The US Dollar Index futures were up modestly, increasing 0.13% to 98.45.

Investor note

Questions around the best investment opportunities for 2026 and how to approach them were also referenced in the session commentary. The text discussed the value of combining high-quality data and analytic tools to support investment decisions, noting a platform that pairs institutional-grade datasets with AI-driven insights. The commentary emphasized that such tools do not guarantee winners but can help identify more opportunities, and it suggested leveraging advanced analytics for portfolio decision making.


This report summarizes the trading session in Brussels and the related commodity and currency moves that accompanied the market action.

Risks

  • Negative market breadth - more declining stocks (50) than advancing ones (42) and 19 unchanged, which can signal uneven market participation, particularly affecting the Healthcare, Technology and Telecoms sectors.
  • Volatility in commodities - a significant fall in gold futures and a concurrent rise in crude and Brent oil prices indicate commodity price swings that can impact energy and materials sectors.
  • Limited currency movement - while EUR/USD and EUR/GBP were essentially unchanged, even small FX shifts combined with commodity swings can introduce earnings and valuation uncertainty for exporters and importers.

More from Stock Markets

Markets Brace for Fed Decision, Durable Goods and Housing Data in Busy Trading Day Apr 28, 2026 FDA Begins Pilot of Real-Time Clinical Trials, Partners With AstraZeneca and Amgen Apr 28, 2026 Erasca Shares Plunge After Patient Death Linked to Experimental Therapy Apr 28, 2026 FDA to Monitor Clinical Trials in Real Time with Industry Partners to Speed Drug Development Apr 28, 2026 Investor Sues Blue Owl Adviser, Alleging Inflated Valuations and Excessive Fees Apr 28, 2026